Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6699871 | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7459428 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US6890898 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US7078381 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
US6699871 (Pediatric) | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 3 months ago) | |
US7326708 (Pediatric) | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
US9439901 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
US9308204 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) |
Steglujan is owned by Msd Sub Merck.
Steglujan contains Ertugliflozin; Sitagliptin Phosphate.
Steglujan has a total of 10 drug patents out of which 5 drug patents have expired.
Expired drug patents of Steglujan are:
Steglujan was authorised for market use on 19 December, 2017.
Steglujan is available in tablet;oral dosage forms.
Steglujan can be used as ertugliflozin in combination with sitagliptin and in further combination with metformin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, ertugliflozin and sitagliptin in combination as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Drug patent challenges can be filed against Steglujan from 19 December, 2021.
The generics of Steglujan are possible to be released after 21 October, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-275) | Sep 17, 2024 |
New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: Ertugliflozin in combination with sitagliptin and in further combination with metformin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; Ertuglif...
Dosage: TABLET;ORAL